A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

251

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions

Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Interventions

DRUG

Camrelizumab、Rivoceranib

Camrelizumab: 200 mg, intravenous infusion. Rivoceranib: 250 mg, oral.

DRUG

Camrelizumab

Camrelizumab: 200 mg, intravenous infusion.

Trial Locations (1)

Zhongshan Hospital, Fudan University, Shanghai

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY